Search CRMD
CorMedix Inc.
Nasdaq · CIK 1410098
Last close7.19
Daily change-0.23 (-3.10%)
10 Years gain-43.16%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CRMD · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
89.6Momentum
100.0Acceleration
100.0Confidence
83.0Annual Revenue13
Quarterly Revenue46
Annual CFO16
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality22.1 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics3.1 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 60.8671 percentage points.
ROIC expansionROIC improved by 126.7197 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 10.6763 percentage points.
Heavy share dilution · HIGHDiluted share count increased 34.0761%.
Key Metrics
Revenue Growth TTM626.77%OK
Revenue CAGR 3Y1,077.48%OK
Gross Margin83.89%OK
Operating Margin47.53%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC95.52%OK
Incremental Operating Margin 3Y54.99%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y34.08%OK
SBC / Revenue4.13%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $311.71M | $275.75M | $150.14M | $175.05M | $172.79M | 88.46% | 48.17% | 55.43% | 94.63% | 80,308 |
| 2025 FY Dec 31, 2024 | $43.47M | $40.28M | -$22.36M | -$50.62M | -$50.73M | 92.66% | -51.43% | -116.7% | -130.44% | 58,872 |
| 2024 FY Dec 31, 2023 | n/a | $0.00 | -$48.96M | -$38.41M | -$38.74M | n/a | n/a | n/a | n/a | 50.9M |
| 2023 FY Dec 31, 2022 | $65,408.00 | $61,674.00 | -$30.62M | -$24.36M | -$24.58M | 94.29% | -46,819.91% | -37,573.53% | n/a | 40.27M |
| 2022 FY Dec 31, 2021 | $190,936.00 | $41,998.00 | -$29.44M | -$21.16M | -$22.58M | 22% | -15,417.51% | -11,826.24% | n/a | 37.67M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $373.37M | sum latest 4 fiscal quarters Revenue | OK | 0001410098-26-000056, 0001213900-25-108777 |
| Revenue Growth TTM | 626.77% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001410098-26-000056, 0001213900-25-108777 |
| Revenue CAGR 3Y | 1,077.48% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001213900-26-023889 |
| Revenue CAGR 5Y | 305.8% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001213900-26-023889 |
| Gross Profit CAGR 3Y | 1,772.53% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001213900-26-023889 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001410098-26-000056, 0001213900-25-108777 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 83.89% | Gross Profit / Revenue | OK | 0001410098-26-000056, 0001213900-25-108777 |
| Operating Margin | 47.53% | Operating Income / Revenue | OK | 0001410098-26-000056, 0001213900-25-108777 |
| ROIC | 95.52% | NOPAT / Average Invested Capital | OK | 0001410098-26-000056, 0001213900-25-108777 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001410098-26-000056 |
| Current Ratio | 2.56x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 4.13% | SBC / Revenue | OK | 0001410098-26-000056, 0001213900-25-108777 |
| Revenue per Diluted Share | $4.04 | Revenue / Diluted Shares | OK | 0001410098-26-000056, 0001213900-25-108777 |